Acetylcholine and epinephrine effects on the embryonic rat heart

Dbh+ catecholaminergic cardiomyocytes contribute to the structure and function of the cardiac conduction system in murine heart

The heterogeneity of functional cardiomyocytes arises during heart development, which is essential to the complex and highly coordinated cardiac physiological function. Yet the biological and physiological identities and the origin of the specialized cardiomyocyte populations have not been fully comprehended. Here we report a previously unrecognised population of cardiomyocytes expressing Dbhgene encoding dopamine beta-hydroxylase in murine heart. We determined how these myocytes are distributed across the heart by utilising advanced single-cell and spatial transcriptomic analyses, genetic fate mapping and molecular imaging with computational reconstruction. We demonstrated that they form the key functional components of the cardiac conduction system by using optogenetic electrophysiology and conditional cardiomyocyte Dbh gene deletion models. We revealed their close relationship with sympathetic innervation during cardiac conduction system formation. Our study thus provides new insights into the development and heterogeneity of the mammalian cardiac conduction system by revealing a new cardiomyocyte population with potential catecholaminergic endocrine function.

Novel cardiac cell subpopulations: Pnmt-derived cardiomyocytes

Diversity among highly specialized cells underlies the fundamental biology of complex multi-cellular organisms. One of the essential scientific questions in cardiac biology has been to define subpopulations within the heart. The heart parenchyma comprises specialized cardiomyocytes (CMs). CMs have been canonically classified into a few phenotypically diverse subpopulations largely based on their function and anatomic localization. However, there is growing evidence that CM subpopulations are in fact numerous, with a diversity of genetic origin and putatively different roles in physiology and pathophysiology. In this chapter, we introduce a recently discovered CM subpopulation: phenylethanolamine-N-methyl transferase (Pnmt)-derived cardiomyocytes (PdCMs). We discuss: (i) canonical classifications of CM subpopulations; (ii) discovery of PdCMs; (iii) Pnmt and the role of catecholamines in the heart; similarities and dissimilarities of PdCMs and canonical CMs; and (iv) putative functions of PdCMs in both physiological and pathological states and future directions, such as in intra-cardiac adrenergic signalling.

Cardiotoxicity of β-mimetic catecholamines during ontogenetic development - possible risks of antenatal therapy

Catecholamines are involved in the regulation of a wide variety of vital functions. The β-adrenergic receptor (β-AR) - adenylyl cyclase system has been identified early in embryogenesis before the heart has received adrenergic innervation. The structure of β-receptors in the immature myocardium is similar to that in adults; there are, however, significant quantitative developmental changes in the inotropic and chronotropic responsiveness. Information on the toxic effect of the β-AR agonists in the immature heart is surprisingly scarce, even though these agents are used in clinical practice both during pregnancy and in early postnatal development. Large doses of β-AR agonists induce malformations of the cardiovascular system; the type of change depends upon the time at which the β-AR agonist was administered during embryogenesis. During postnatal ontogeny, the cardiotoxicity of β-AR agonists increased from birth to adulthood. It seems likely that despite interspecies differences, developmental changes in the cardiac sensitivity to β-AR agonists may exist in all mammals, depending on the degree of maturation of the system involved in β-adrenergic signaling. All the existing data draw attention to the possible harmful consequences of the clinical use of β-AR agonists during early phases of cardiac development. Late effects of the early disturbances of the cardiac muscle cannot be excluded.

Physiological and genomic consequences of adrenergic deficiency during embryonic/fetal development in mice: impact on retinoic acid metabolism

Adrenergic hormones are essential for early heart development. To gain insight into understanding how these hormones influence heart development, we evaluated genomic expression changes in embryonic hearts from adrenergic-deficient and wild-type control mice. To perform this study, we used a mouse model with targeted disruption of the Dopamine β-hydroxylase (Dbh) gene, whose product is responsible for enzymatic conversion of dopamine into norepinephrine. Embryos homozygous for the null allele (Dbh(-/-)) die from heart failure beginning as early as embryonic day 10.5 (E10.5). To assess underlying causes of heart failure, we isolated hearts from Dbh(-/-) and Dbh(+/+) embryos prior to manifestation of the phenotype and examined gene expression changes using genomic Affymetrix 430A 2.0 arrays, which enabled simultaneous evaluation of >22,000 genes. We found that only 22 expressed genes showed a significant twofold or greater change, representing ~0.1% of the total genes analyzed. More than half of these genes are associated with either metabolism (31%) or signal transduction (22%). Remarkably, several of the altered genes encode for proteins that are directly involved in retinoic acid (RA) biosynthesis and transport. Subsequent evaluation showed that RA concentrations were significantly elevated by an average of ~3-fold in adrenergic-deficient (Dbh(-/-)) embryos compared with controls, thereby suggesting that RA may be an important downstream mediator of adrenergic action during embryonic heart development.

Ablation of Nkx2-5 at mid-embryonic stage results in premature lethality and cardiac malformation

AIMS

Human congenital heart disease linked to mutations in the homeobox transcription factor, NKX2-5, is characterized by cardiac anomalies, including atrial and ventricular septal defects as well as conduction and occasional defects in contractility. In the mouse, homozygous germline deletion of Nkx2-5 gene results in death around E10.5. It is, however, not established whether Nkx2-5 is necessary for cardiac development beyond this embryonic stage. Because human NKX2-5 mutations are related to septum secundum type atrial septal defects (ASD), we hypothesized that Nkx2-5 deficiency during the processes of septum secundum formation may cause cardiac anomalies; thus, we analysed mice with tamoxifen-inducible Nkx2-5 ablation beginning at E12.5 when the septum secundum starts to develop.

METHODS AND RESULTS

Using tamoxifen-inducible Nkx2-5 gene-targeted mice, this study demonstrates that Nkx2-5 ablation beginning at E12.5 results in embryonic death by E17.5. Analysis of mutant embryos at E16.5 shows arrhythmias, contraction defects, and cardiac malformations, including ASD. Quantitative measurements using serial section histology and three-dimensional reconstruction demonstrate growth retardation of the septum secundum and enlarged foramen ovale in Nkx2-5-ablated embryos. Functional cardiac defects may be attributed to abnormal expression of transcripts critical for conduction and contraction, including cardiac voltage-gated Na(+) channel pore-forming α-subunit (Na(v)1.5-α), gap junction protein connexin40, cardiac myosin light chain kinase, and sarcolipin within 4 days after tamoxifen injection.

CONCLUSION

Nkx2-5 is necessary for survival after the mid-embryonic stage for cardiac function and formation by regulating the expression of its downstream target genes.

Intrinsic cardiac catecholamines help maintain beating activity in neonatal rat cardiomyocyte cultures

In the present study, we identify intrinsic cardiac adrenergic (ICA) cells in the neonatal rat heart using immunofluorescent histochemical staining techniques with antibodies that specifically recognize the major enzymes in the catecholamine biosynthetic pathway. ICA cells are most concentrated near the endocardial surface of ventricular myocardium, but are also found sporadically throughout the heart. In primary cultures of neonatal rat cardiomyocytes, ICA cells are closely associated with clusters of cardiomyocytes. To investigate a potential role for intrinsically produced catecholamines, we recorded beating rates in the presence and absence of the catecholamine-depleting agent reserpine or the adrenergic receptor blockers prazosin and timolol using videomicroscopy and photodiode sensors. Our results show that beating rates slow significantly when endogenous catecholamines are depleted or when their action is blocked with either a beta- or an alpha1-adrenergic receptor antagonist. These data indicate that intrinsic cardiac catecholamines help to maintain beating rates in neonatal rat cardiomyocyte cultures via stimulation of alpha1- and beta-adrenergic receptors. This information should help to increase our understanding of the physiologic mechanisms governing cardiovascular function in neonates.

Generating Mouse Models for Studying the Function and Fate of Intrinsic Cardiac Adrenergic Cells

Embryos lacking the ability to synthesize epinephrine and norepinephrine die (probably due to cardiac failure) without exogenous supplementation while mutant neonates can grow into fertile adults without supplementation. These experiments define a critical period during embryogenesis, when norepinephrine and/or epinephrine are essential for mouse development. The critical period is prior to sympathetic innervation of the heart and prior to synthesis of catecholamines by the adrenal medullae. Recent work indicates that the developing heart is likely to be a major source of catecholamines in the developing mammalian embryo. The spatial pattern of biosynthetic enzymes suggests an association of the intrinsic cardiac adrenergic cells with the developing pacemaker and cardiac conduction cells. To address the functional characteristics and the fate of these cardiac adrenergic cells, we have developed two mouse models that allow us to identify and to characterize the adrenergic cells and their descendants.

Ontogeny of humoral heart rate regulation in the embryonic mouse

Catecholamines, acetylcholine, and adenosine are known to influence cardiac function, yet the effects of these agents on mammalian embryonic myocardium are largely unknown. To address this issue, we compared the chronotrophic effects of adenosinergic, adrenergic, and muscarinic agents on cultured murine embryos from postcoital day (PC) 8.0, when the fusing heart tubes first begin to beat, to PC 14, when cardiogenesis is essentially complete. At PC 8.0 and older, A(1)-adenosine receptor (A(1)AR) activation significantly decreased heart rates. Adrenergic stimulation caused modest increases in heart rates (145-155% of baseline) beginning at PC 9.0. Muscarinic activation decreased heart rates only after PC 13. When receptor gene expression was examined, A(1)ARs and beta(1)ARs were expressed in isolated hearts as early as PC 9.0, and beta(2)ARs and m(2)-muscarinic receptor genes were expressed at PC 11.0. These results identify the adenosinergic system as the earliest and most potent regulator of embryonic cardiac function and show that prenatal responsiveness to catecholamines and acetylcholine develops at later embryonic stages.

Embryonic epinephrine synthesis in the rat heart before innervation: association with pacemaking and conduction tissue development

Epinephrine is a potent neurotransmitter and hormone that can influence cardiac performance beginning shortly after the first myocardial contractions occur in developing vertebrate embryos. In the present study, we provide evidence that the heart itself may produce epinephrine during embryonic development. Using antibodies that selectively recognize the catecholamine biosynthetic enzymes, tyrosine hydroxylase, dopamine ss-hydroxylase, and phenylethanolamine N-methyltransferase, we used coimmunofluorescent staining techniques to identify cardiac cells that have the capability of producing catecholamines. Initially, cells expressing catecholamine biosynthetic enzymes were found interspersed throughout the myocardium, but by embryonic day 11.5 (E11.5), they became preferentially localized to the dorsal venous valve and atrioventricular canal regions. As development proceeded, catecholamine biosynthetic enzyme expression decreased in these regions but became quite strong along the crest of the interventricular septum by E16.5. This expression pattern was also transient, decreasing in the ventricular septum by E19.5. These data are consistent with a transient and progressive association of catecholamine-producing cells within regions of the heart that become the sinoatrial node, atrioventricular node, and bundle of His. This is the first evidence demonstrating that intrinsic cardiac adrenergic cells may be preferentially associated with early pacemaking and conduction tissue development.

beta-adrenergic modulation of L-type Ca2+-channel currents in early-stage embryonic mouse heart

Little information is available concerning the modulation of cardiac function by beta-adrenergic agonists in early-stage embryonic mammalian heart. We have examined the effects of isoproterenol (Iso) on the spontaneous beating rate and action potential (AP) configuration in embryonic mouse hearts at 9.5 days postcoitum (dpc), just 1 day after they started to beat. Iso (3 microM) increased the spontaneous beating rate in whole hearts, dissected ventricles, and isolated ventricular myocytes. In ventricular myocytes, Iso also increased the slope of the pacemaker potential and the action potential duration but decreased the maximum upstroke velocity. In whole cell voltage-clamp experiments, the Ca2+-channel currents were measured as Ba2+ currents (IBa). In 9.5-dpc myocytes, IBa was enhanced significantly from -4.7 +/- 0.9 to -6.7 +/- 1.2 pA/pF (by 52.4 +/- 14.8%, n = 10) after the application of Iso. Propranolol (3 microM) reversed the effect of Iso. Forskolin (For, 10 microM) produced an increase in IBa by 95.5 +/- 18.8% (n = 8). In ventricular myocytes at a late embryonic stage (18 dpc), 3 microM Iso caused an appreciably greater increase in IBa from -6.2 +/- 0.5 to -14.5 +/- 2.2 pA/pF (by 137.8 +/- 33.0%, n = 8), whereas the increase in IBa by 10 microM For (by 120.0 +/- 23.0%, n = 7) was comparable to that observed in the early stage (9.5 dpc). These results indicate that the L-type Ca2+-channel currents are modulated by beta-adrenergic receptors in the embryonic mouse heart as early as 9.5 dpc, probably via a cAMP-dependent pathway.

Fetal ethanol exposure diminishes hippocampal beta-adrenergic receptor density while sparing muscarinic receptors during development

Because of ostensible effects of fetal exposure to ethanol on cardiac and memory functions, beta-adrenergic and muscarinic receptor binding were surveyed in hippocampus and heart in 8- and 17-day-old rat pups. Pregnant, multiparous rats were intubated with either 6 g/kg ethanol or isocaloric dextrose twice daily from gestational days 10-16. At birth, offspring were fostered to untreated mothers. Pups exposed to ethanol had diminished birth weights, although there was no difference in the amount of weight gain by ethanol and control dams during gestation, nor in litter size. Ethanol pups remained smaller than control pups, but this difference was significant only until 8 days of age. At 17 days of age, ethanol pups had fewer hippocampal beta-adrenergic receptors than age-matched controls; muscarinic receptors and CA1 cell densities were not disparate. Parallel studies suggested that approximately 50% of the hippocampal beta-adrenergic receptors in 8-day-olds were of the beta 1 and beta 2 subtypes, while by 17 days of age approximately 70% of the receptors were beta 1. There was an ontogenetic increment in both beta-adrenergic and muscarinic binding from 8 to 17 days of age in hippocampus. No differences between age or drug groups were found in the binding measures in heart tissue. The present findings indicate that fetal ethanol treatment affects developmental measures and beta-adrenergic receptors in the hippocampus in a quasi-selective manner, but not hippocampal CA1-cell density.

Acetylcholinesterase in prenatal rat heart: a marker for the early development of the cardiac conductive tissue?

In rat embryos, acetylcholinesterase (AChE, EC 3.1.1.7) activity is present in a continuous sleeve of myocytes that extends from the myocardium that is adjacent to the atrioventricular endocardial cushions via the ventricular trabeculae to the outflow tract. No activity is found in the atrial roof, in the ventricular walls and in the interventricular septum except for its subendocardial surface. AChE-positive cells are first identified in 11-day rat embryos, while the prototypical distribution is best demonstrable in 13-day embryos. Part of the AChE-positive cell system is identifiable as a precursor of the adult conduction system by topographical criteria in 16-day fetuses and by morphological criteria in 20-day fetuses. At birth (2 days later), AChE activity has disappeared from the cardiac myocytes except for a ring of tissue at the atrial side of the atrioventricular junction. These findings suggest that the embryonic heart can be divided into an upstream myocardium that has no AChE activity and a downstream myocardium that is characterized by the presence of AChE. Furthermore they suggest that an acetylcholine-dependent mechanism may be responsible for the retardation of the depolarization wave in the downstream parts of the heart. Finally they show that the adult conduction system is formed by a transdifferentiation of part of a far more extensive embryonic precursor system.

Muscarinic acetylcholine receptors in the heart of rats before and after birth

Atropine-displaceable binding of (3H)quinuclidinyl benzilate (QNB) to homogenates was used to identify the muscarinic binding sites in rat heart atria and ventricles and to investigate developmental changes in their concentration and binding properties between the 15th day of prenatal life and 3 months after birth. On the 15th day of prenatal life, muscarinic binding sites were already present in the heart. Their concentration increased steeply between the 15th and 19th days of prenatal development; in the atria, it remained high until the 1st day after birth and thereafter it diminished throughout the postnatal life, while in the ventricles the decrease started before the first postnatal day. The concentration of the binding sites was 1.8-3.0 times higher in the atria than in the ventricles at all time points investigated. Their affinity for QNB (the antagonist) was the same in the atria and ventricles and did not change during postnatal development (KD of 17.8 pmol/l at an infinitely low concentration of the binding sites). The binding of carbamoylcholine (the agonist) to muscarinic binding sites was analysed in experiments with the displacement of (3H)QNB binding, assuming the presence of high- and low-affinity binding sites for agonists. The proportion between the concentrations of the two classes of agonist binding sites is close to 1:1 both in the atria and the ventricles and does not change with age. No statistical significant differences were discovered between the affinities of the high- and low-affinity binding sites for carbamoylcholine between the atria and the ventricles and between new-born and adult rats.(ABSTRACT TRUNCATED AT 250 WORDS)

The cardiovascular effects of circulating catecholamines in fetal sheep

1. Adrenaline and noradrenaline have been infused into the fetal sheep to produce plasma concentrations comparable to those seen during hypoxia and the cardiovascular changes compared with those seen in response to hypoxia. The effect of isoprenaline, methoxamine, and beta- and alpha-adrenergic antagonists were also investigated. 2. There were no significant changes in the blood gas values during any of the infusions except for a mean fall in pH of 0.04 during adrenaline infusion. 3. Adrenaline caused a fall in the fetal heart rate followed by a rise above the control value after 15-20 min. The fall in heart rate was abolished when the rise in blood pressure was blocked with phentolamine. The rise in heart rate was blocked by propranolol. The exact cause of the biphasic changes in heart rate during adrenaline infusion is not clear. 4. A fall in heart rate was not seen with noradrenaline; a small rise was. Propranolol changed this into a fall in heart rate while phentolamine increased the size of the heart rate rise. 5. Phentolamine alone increased the fetal heart rate by 25% and reduced blood pressure by 12%; propranolol alone reduced heart rate by 14% and had no effect on blood pressure. Isoprenaline increased fetal heart rate and reduced blood pressure. 6. The incidence of fetal breathing movements was highly variable. Despite this a significant increase was observed during adrenaline infusion. None of the other infusions had consistent effects. 7. The role of the circulating catecholamines in mediating or modifying the cardiovascular responses to hypoxia in the fetal sheep is discussed.

Postnatal development of adrenergic and cholinergic sensitivity in the isolated rat atria

The sensitivity to adrenergic drugs in isolated rat atria increased with the postnatal development. The cholinergic chronotropic sensitivity did not further change after birth.

Plasma catecholamines in foetal and adult sheep

1. Foetal and maternal plasma catecholamine concentrations were measured during and after hypoxia (mean maternal Pa,02 44mmHg) in chronically catheterized sheep, 118-141 days pregnant. 2. In most foetuses the initial plasma catecholamines were smaller than 0.07 ng/ml. During hypoxia plasma adrenaline and noradrenaline always rose; there was a rise in arterial pressure and a fall in heart rate. 3. The initial catecholamine concentration in the ewes was smaller than 0.05-2.3 ng/ml. During hypoxia there was no consistent change; the maternal plasma concentrations were less than the foetal. 4. Infusion of adrenaline at 0.3 mug kg(-1) min(-1) to the ewe resulted in plasma catecholamine concentrations higher than those observed during hypoxia. There was a rise in heart rate but no consistent change in arterial pressure. 5. Infusion of adrenaline 0.4 mug kg(-1) min(-1) into the foetal jugular vein caused a rise in plasma concentration similar to that seen during hypoxia. There was a rise in heart rate but no significant change in arterial pressure. 6. The half-life of adrenaline and of noradrenaline in the maternal and foetal circulation was 0.25-1 min. There was no evidence of transfer of labelled catecholamine across the placenta.

Maturation of responsiveness to cardioactive drugs. Differential effects of acetylcholine, norepinephrine, theophylline, tyramine, glucagon, and dibutyryl cyclic AMP on atrial rate in hearts of fetal mice

Freshly isolated hearts of fetal mice of gestational ages ranging between 12 and 22 days (term) were exposed to several concentrations of a variety of chronotropic agents. Acetylcholine (10(-4)-10(-2) M) caused marked bradycardia in all hearts, even after only 12-14 days' gestation (i.e., even before cardiac innervation had occurred), and the intensity of the response increased steadily with advancing age throughout gestation. Responsiveness to norepinephrine was present but minimal at 12-14 days, so that mean atrial rate rose by < 10% with a maximal concentration of the drug (10(-5) M); responsiveness became more marked by 15-16 days (just after the time atrial innervation is thought to begin) and still greater effects appeared just before term. Glucagon had no effect in hearts of < 17 days' gestational age, but caused tachycardia thereafter, indicating that cardiac responsiveness to glucagon differentiates later than does responsiveness to norepinephrine. Responses to theophyl-line in 12-14 day hearts exceeded those to norepinephrine, indicating that the drug can affect heart rate independently of its ability to cause release of endogenous catecholamines. In contrast, tyramine caused no response until 21-22 days, well after the time the beta-receptor has differentiated and after innervation is fairly well developed, suggesting that the drug's primary sympathomimetic effect is indirect rather than direct. Dibutyryl cyclic AMP did not cause tachycardia at any fetal age. It is concluded that maturation of responsiveness of the mouse heart to cardioactive drugs develops in specific patterns for different agents. The identification of differential patterns of maturation for various drugs may provide valuable means for characterizing the differentiation of specific receptors and for investigating possible mechanisms of action of the drugs.